Prognostic Significance of ESR1 Amplification and ESR1 PvuII, CYP2C19*2, UGT2B15*2 Polymorphisms in Breast Cancer Patients

PLoS ONE

Volumn 8, Issue 8, 2013, Pages

  Markiewicz, Aleksandra ^a,b   Wełnicka Jaśkiewicz, Marzena ^a   Skokowski, Jarosław ^a   Jaśkiewicz, Janusz ^a   Szade, Jolanta ^a   Jassem, Jacek ^a   Zaczek, Anna J ^a  

^a MEDICAL UNIVERSITY OF GDANSK   (Poland)

^b MEDICAL UNIVERSITY OF WARSAW   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 2C19; ESTROGEN RECEPTOR ALPHA; GENOMIC DNA; TAMOXIFEN;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CLINICAL FEATURE; CONTROLLED STUDY; CYP2C19 GENE; DISEASE FREE SURVIVAL; ESR1 GENE; GENE; GENE AMPLIFICATION; GENE DOSAGE; GENE FREQUENCY; GENE FUNCTION; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; HUMAN TISSUE; LEUKOCYTE; MAJOR CLINICAL STUDY; NUCLEIC ACID PROBE; OVERALL SURVIVAL; REAL TIME POLYMERASE CHAIN REACTION; SURVIVAL RATE; SURVIVAL TIME; UGT2B15 GENE;

ANTINEOPLASTIC AGENTS, HORMONAL; ARYL HYDROCARBON HYDROXYLASES; BREAST; BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; ESTROGEN RECEPTOR ALPHA; FEMALE; GENE AMPLIFICATION; GENE DOSAGE; GLUCURONOSYLTRANSFERASE; HUMANS; MIDDLE AGED; POLYMORPHISM, GENETIC; PROGNOSIS; TAMOXIFEN;

EID: 84881328405     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0072219     Document Type: Article

References (37)

1. Bocchinfuso WP, Korach KS, (1997) Mammary Gland Development and Tumorigenesis in Estrogen Receptor Knockout Mice. J Mammary Gland Biol Neoplasia 2: 323-334. doi:10.1023/A:1026339111278. PubMed: 10935020.
2. Yoshidome K, Shibata MA, Couldrey C, Korach KS, Green JE, (2000) Estrogen promotes mammary tumor development in C3(1)/SV40 large T-antigen transgenic mice: paradoxical loss of estrogen receptoralpha expression during tumor progression. Cancer Res 60: 6901-6910. PubMed: 11156389.
3. EBCTCG (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365: 1687-1717. doi:10.1016/S0140-6736(05)66544-0. PubMed: 15894097.
4. Musgrove EA, Sutherland RL, (2009) Biological determinants of endocrine resistance in breast cancer. Nat Rev Cancer 9: 631-643. doi:10.1038/nrc2713. PubMed: 19701242.
5. Vincent-Salomon A, Raynal V, Lucchesi C, Gruel N, Delattre O, (2008) ESR1 gene amplification in breast cancer: a common phenomenon? Nat Genet 40: 809; author reply 810-802 doi:10.1038/ng0708-809b. PubMed: 1858396718583966.
6. Tomita S, Zhang Z, Nakano M, Ibusuki M, Kawazoe T, et al. (2009) Estrogen receptor alpha gene ESR1 amplification may predict endocrine therapy responsiveness in breast cancer patients. Cancer Sci 100: 1012-1017. doi:10.1111/j.1349-7006.2009.01145.x. PubMed: 19320640.
7. Holst F, Stahl PR, Ruiz C, Hellwinkel O, Jehan Z, et al. (2007) Estrogen receptor alpha (ESR1) gene amplification is frequent in breast cancer. Nat Genet 39: 655-660. doi:10.1038/ng2006. PubMed: 17417639.
8. Nielsen KV, Ejlertsen B, Müller S, Møller S, Rasmussen BB, et al. (2011) Amplification of ESR1 may predict resistance to adjuvant tamoxifen in postmenopausal patients with hormone receptor positive breast cancer. Breast Cancer Res Treat 127: 345-355. doi:10.1007/s10549-010-0984-y. PubMed: 20556506.
9. Ejlertsen B, Aldridge J, Nielsen KV, Regan MM, Henriksen KL, et al. (2012) Prognostic and predictive role of ESR1 status for postmenopausal patients with endocrine-responsive early breast cancer in the Danish cohort of the BIG 1-98 trial. Annals Oncology Off J Eur Soc Medical Oncology/ESMO 23: 1138-1144. doi:10.1093/annonc/mdr438. PubMed: 21986093.
10. Cai Q, Shu XO, Jin F, Dai Q, Wen W, et al. (2003) Genetic polymorphisms in the estrogen receptor alpha gene and risk of breast cancer: results from the Shanghai Breast Cancer Study. Cancer epidemiology, biomarkers & prevention: a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 12: 853-859.
11. Hill SM, Fuqua SA, Chamness GC, Greene GL, McGuire WL, (1989) Estrogen receptor expression in human breast cancer associated with an estrogen receptor gene restriction fragment length polymorphism. Cancer Res 49: 145-148. PubMed: 2562795.
12. Crewe HK, Notley LM, Wunsch RM, Lennard MS, Gillam EM, (2002) Metabolism of tamoxifen by recombinant human cytochrome P450 enzymes: formation of the 4-hydroxy, 4'-hydroxy and N-desmethyl metabolites and isomerization of trans-4-hydroxytamoxifen. Drug Metab Dispos Biol Fate Chem 30: 869-874. doi:10.1124/dmd.30.8.869. PubMed: 12124303.
13. Desta Z, Zhao X, Shin JG, Flockhart DA, (2002) Clinical significance of the cytochrome P450 2C19 genetic polymorphism. Clin Pharmacokinet 41: 913-958. doi:10.2165/00003088-200241120-00002. PubMed: 12222994.
14. Nishiyama T, Ogura K, Nakano H, Ohnuma T, Kaku T, et al. (2002) Reverse geometrical selectivity in glucuronidation and sulfation of cis- and trans-4-hydroxytamoxifens by human liver UDP-glucuronosyltransferases and sulfotransferases. Biochem Pharmacol 63: 1817-1830. doi:10.1016/S0006-2952(02)00994-2. PubMed: 12034366.
15. Lévesque E, Beaulieu M, Green MD, Tephly TR, Bélanger A, et al. (1997) Isolation and characterization of UGT2B15(Y85): a UDP-glucuronosyltransferase encoded by a polymorphic gene. Pharmacogenetics 7: 317-325. doi:10.1097/00008571-199708000-00007. PubMed: 9295060.
16. Dezentje VO, Schaik RHV, Vletter-Bogaartz JM, Wessels JA, Hille ET, et al. (2010) Pharmacogenetics of tamoxifen in relation to disease-free survival in a Dutch cohort of the tamoxifen exemestane adjuvant multinational (TEAM) trial. 2010 ASCO, Annual Meeting.
17. Ruiter R, Bijl MJ, van Schaik RH, Berns EM, Hofman A, et al. (2010) CYP2C19*2 polymorphism is associated with increased survival in breast cancer patients using tamoxifen. Pharmacogenomics 11: 1367-1375. doi:10.2217/pgs.10.112. PubMed: 21047200.
18. Nowell SA, Ahn JY, Rae JM, Scheys JO, Trovato A, et al. (2005) Association of genetic variation in tamoxifen-metabolizing enzymes with overall survival and recurrence of disease in breast cancer patients. Breast Cancer Res Treat 91: 249-258. doi:10.1007/s10549-004-7751-x. PubMed: 15952058.
19. Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thürlimann B, et al. (2011) Strategies for subtypes--dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol 22: 1736-1747. doi:10.1093/annonc/mdr304. PubMed: 21709140.
20. Zaczek A, Markiewicz A, Jaskiewicz J, Pienkowski T, Rhone P, et al. (2010) Development and Evaluation of Clinical Significance of a Real-Time PCR Assay for TOP2A Copy Number Determination in Breast Cancer. Ann Oncol 21: 57-57.
21. Hellemans J, Mortier G, De Paepe A, Speleman F, Vandesompele J, (2007) qBase relative quantification framework and software for management and automated analysis of real-time quantitative PCR data. Genome Biol 8: R19-. PubMed: 17291332.
22. Yaich L, Dupont WD, Cavener DR, Parl FF, (1992) Analysis of the PvuII restriction fragment-length polymorphism and exon structure of the estrogen receptor gene in breast cancer and peripheral blood. Cancer Res 52: 77-83. PubMed: 1345763.
23. de Morais SM, Wilkinson GR, Blaisdell J, Nakamura K, Meyer UA, et al. (1994) The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans. J Biol Chem 269: 15419-15422. PubMed: 8195181.
24. Ebeshi B, Bolaji O, Masimirembwa C, (2011) Allele and genotype frequencies of cytochrome P450 2B6 and 2C19 genetic polymorphisms in the Nigerian populations: Possible implication on anti-retroviral and anti-malarial therapy. Int J Med Medical Sciences 3: 193-200.
25. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, et al. (2005) REporting recommendations for tumour MARKer prognostic studies (REMARK). Br J Cancer 93: 387-391. doi:10.1038/sj.bjc.6602678. PubMed: 16106245.
26. Reis-Filho JS, Drury S, Lambros MB, Marchio C, Johnson N, et al. (2008) ESR1 gene amplification in breast cancer: a common phenomenon? Nat Genet 40: 809-810; author reply 810-802 doi:10.1038/ng0708-809b. PubMed: 1858396718583966.
27. Ooi A, Inokuchi M, Harada S, Inazawa J, Tajiri R, et al. (2012) Gene amplification of ESR1 in breast cancers--fact or fiction? A fluorescence in situ hybridization and multiplex ligation-dependent probe amplification study. J Pathol 227: 8-16. doi:10.1002/path.4064. PubMed: 22170254.
28. Moelans CB, Monsuur HN, de Pinth JH, Radersma RD, de Weger RA, et al. (2010) ESR1 amplification is rare in breast cancer and is associated with high grade and high proliferation: a multiplex ligation-dependent probe amplification study. Anal Cell Pathol 33: 13-18. PubMed: 215417332042168820966540.
29. Brown LA, Hoog J, Chin SF, Tao Y, Zayed AA, et al. (2008) ESR1 gene amplification in breast cancer: a common phenomenon? Nat Genet 40: 806-807; author reply 810-802 doi:10.1038/ng0708-806. PubMed: 18583964.
30. Reynisson E, Josefsen MH, Krause A, Hoorfar J, (2006) Evaluation of probe chemistries and platforms to improve the detection limit of real-time PCR. J Microbiol Methods 66: 206-216. doi:10.1016/j.mimet.2005.11.006. PubMed: 16364478.
31. Albertson DG, (2012) ESR1 amplification in breast cancer: controversy resolved? J Pathol 227: 1-3. doi:10.1002/path.3999. PubMed: 22322671.
32. Lin CH, Liu JM, Lu YS, Lan C, Lee WC, et al. (2013) Clinical significance of ESR1 gene copy number changes in breast cancer as measured by fluorescence in situ hybridisation. J Clin Pathol, 66: 140-5. PubMed: 23268322.
33. Horlings HM, Bergamaschi A, Nordgard SH, Kim YH, Han W, et al. (2008) ESR1 gene amplification in breast cancer: a common phenomenon? Nat Genet 40: 807-808. doi:10.1038/ng0708-807. PubMed: 18583965.
34. Ryan J, Canonico M, Carcaillon L, Carrière I, Scali J, et al. (2012) Hormone treatment, estrogen receptor polymorphisms and mortality: a prospective cohort study. PLOS ONE 7: e34112. doi:10.1371/journal.pone.0034112. PubMed: 22457817.
35. Schroth W, Antoniadou L, Fritz P, Schwab M, Muerdter T, et al. (2007) Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes. J Clin Oncol 25: 5187-5193. doi:10.1200/JCO.2007.12.2705. PubMed: 18024866.
36. Okishiro M, Taguchi T, Kim SJ, Shimazu K, Tamaki Y, et al. (2009) Genetic Polymorphisms of CYP2D6*10 and CYP2C19* 2,*3 Are not Associated With Prognosis, Endometrial Thickness, or Bone Mineral Density in Japanese Breast Cancer Patients Treated With Adjuvant Tamoxifen. Cancer 115: 952-961. doi:10.1002/cncr.24111. PubMed: 19156902.
37. Altshuler DL, Durbin RM, Abecasis GR, Bentley DR, Chakravarti A, et al. (2010) A map of human genome variation from population-scale sequencing. Nature 467: 1061-1073. doi:10.1038/nature09534. PubMed: 20981092.